Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 248-420-5 | CAS number: 27344-06-5
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Sensitisation data (human)
Administrative data
- Endpoint:
- sensitisation data (humans)
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Study period:
- From January 22 to 26, 2001.
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: The test procedure cannot be subsumed under a testing guideline, nevertheless are well documented and scientifically acceptable. The purity of the substance is low.
Data source
Reference
- Reference Type:
- other company data
- Title:
- Unnamed
- Year:
- 2 001
- Report date:
- 2001
Materials and methods
- Type of sensitisation studied:
- skin
- Study type:
- study with volunteers
- Principles of method if other than guideline:
- Procedure based on that described in PROTOCOL RIPT24; ism.13 .DEC.1999.
- GLP compliance:
- not specified
Test material
- Reference substance name:
- Disodium 4,4'-bis[[4-anilino-6-[(2-carbamoylethyl)(2-hydroxyethyl)amino]-1,3,5,-triazin-2-yl]amino]stilbene-2,2'-disulphonate
- EC Number:
- 248-420-5
- EC Name:
- Disodium 4,4'-bis[[4-anilino-6-[(2-carbamoylethyl)(2-hydroxyethyl)amino]-1,3,5,-triazin-2-yl]amino]stilbene-2,2'-disulphonate
- Cas Number:
- 27344-06-5
- Molecular formula:
- C42H46N14O10S2.2Na
- IUPAC Name:
- disodium 4,4'-bis[[4-anilino-6-[(2-carbamoylethyl)(2-hydroxyethyl)amino]-1,3,5,-triazin-2-yl]amino]stilbene-2,2'-disulphonate
Constituent 1
Method
- Type of population:
- general
- Ethical approval:
- confirmed and informed consent free of coercion received
- Subjects:
- - Number of subjects exposed: 111.
- Sex: 77 female, 34 males.
- Age: 19 - 75 (female), 21 - 91 (males). - Route of administration:
- dermal
- Details on study design:
- ADMINISTRATION
- Test site: left site of the back.
Type of device: occlusive patching devices were used to convey the product to the skin and to maintain it on its assigned site on each subject. These devices consisted of a 2 cm x 2 cm absorbent pad centered on the adhesive-coated surface of a 4 cm x 4 cm water-impermeable plastic film.
Preparation of a patching device: prior to application, the webril pad of a patching device was infused with 150 ml of the test material.
Applying a patching device:
- Each device was positioned on its designated site on a subject with the moistened pad in contact with the skin.
- Firm pressure was applied to the backing of the device to effect intimate contact of the product with the skin and to bond the adhesive of the flanges fast to the surrounding skin.
Removing a patching device and its contents:
- Devices were removed in the clinic by staff personnel approximately twenty-four hours after they were applied.
- A technician peeled the device off as gently as was feasible when a subject returned.
GRADING PROCEDURE:
I) lf no adverse effect was discernable, the technician took no action to change the default "0".
2) If an adverse effect was detected, the technician entered a grade to indicate her assessment of the response's intensity. This entry replaced the default "0".
Grades ≥ or a decrease in value >2 grades, had to be validated.
STAGES OF INFLAMMATION, VISIBLE CHANGE, CLINICAL SIGNIFICANCE has been evaluated.
Limit levels were defined. See table 1.
SCHEDULE PF PROCEDURES
a. Initial/Induction Phase: from week 1 to week 4, application ad observation.
b. Intermediate phase: week 4, examination.
b. Challenge/Diagnostic Phase: from week 5 to week 6, observation.
c. Follow up phase: from week 6 to week 7, information collection.
Results and discussion
- Results of examinations:
- INITIAL/INDUCTION PHASE
No responses were noted on any of the III subjects who participated in the induction phase of the study. The absence of responses during this phase serves to characterize the product as one that is devoid of clinically significant skin irritating propensities.
CHALLENGE PHASE
No responses were noted on any of the 104 subjects who participated in the challenge phase of the study. The absence of responses during this phase serves to characterize the product as one that is devoid of clinically significant skin-sensitizing propensities.
FOLLOW-UP PHASE
The investigator received no communications from any of the subjects during this period that provided a basis for altering his opinion concerning the safety of the product.
GLOBAL
Under the conditions prevailing in this patch test study, the product was found to be incapable of eliciting clinically significant skin damage on any of the one-hundred-and-eleven individuals concerning whom data were acquired.
Applicant's summary and conclusion
- Conclusions:
- Non sensitising.
- Executive summary:
Method
The skin sensitizing potentials of the test item was assessed in a test on humans, with a procedure based on that described in PROTOCOL RIPT24; ism.13 .DEC.1999, on one-hundred and eleven qualified volunteers.
The regimen called for four twenty-four hour applications of the sample conducted seriatim during each of weeks 1, 2, 3, and 5 on assigned skin sites on the back of each subject.
Examinations of the contacted skin and grading of its condition were conducted within moments after devices containing the sample were removed.
Results
Weeks 1, 2, and 3 formed the Initial or Induction Phase of the regimen.
Data were acquired on one-hundred-and-eleven subjects during this phase.
No adverse effects were detected on any of the subjects during this phase.
The Challenge or Diagnostic Phase of the regimen was conducted during week 5.
Data were acquired on one-hundred and-four subjects during this phase.
No adverse effects were detected on any of the subjects during this phase.
On the basis of the above-cited observations, the test item was found to be devoid of skin-sensitizing propensities that can be detected under the conditions of this patch test procedure.
Conclusion
The investigator concluded that the data do not contraindicate usages entailing conditions of contact commensurate with those that prevailed during the course of the study.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
